We have previously developed several nanomaterial‐based drug delivery systems with tumor‐targeting, controlled‐release, and biocompatible properties for cancer treatment, all demonstrating satisfactory antitumor activity.[20, 50, 51] Building on these functional and mechanistic findings, we proposed that HECTD2 could serve as a potential therapeutic target for cancer treatment. The gene discussed is HECTD2; the disease is cancer.